By Denise Mann
HealthDay Reporter
MONDAY, Oct. 24, 2022 (HealthDay News) — For the millions of people who live with vitiligo, a disease that robs the skin of its natural color, a newly approved cream called ruxolitinib (Opzelura) is quickly becoming a game changer.
The U.S. Food and Drug Administration approved ruxolitinib for vitiligo in people aged 12 and older in July. The drug, part of a class known as Janus kinase (JAK) inhibitors, targets JAK, a molecule involved in the development and progression of vitiligo.
About half of folks with vitiligo who used the cream got 75% or more pigment back on the…
